Effect of the types of pretreatment imaging modalities on the treatment response to palliative radiation for painful bone metastases from solid cancer: a single-center retrospective analysis

Table 3 Univariate analysis of patents divided into the response and non-response groups

	Response group	Non-response group	p-value
Age, years; median (range)	67 (35–89)	64 (24–77)	0.21
Sex (Male: Female)	60:45	18:8	0.18
Primary site (Lungs: GU tract: GI tract: Breasts: HN: Thyroid: Gyne: Unknown)	27:26:29:5:4:4:4:6	8:8:5:1:1:0:0:3	0.69
Histology (SCC: Adeno: Small: CC: Others: Unknown)	5:53:4:17:24:2	4:13:0:5:3:1	0.27
Metastases site (Vertebral or non-vertebral)	67:38	19:7	0.57
Bone metastases type (Osteolytic: Osteoblastic: Mixed)	72:25:8	16:9:1	0.47
Pathological fracture (Present: Absent)	17:88	7:19	0.21
MRI	43 (41%)	11 (42%)	0.54
Bone scintigraphy	45 (43%)	11 (42%)	0.57
¹⁸FDG-PET	12 (11%)	2 (8%)	0.45

GU Genitourinary, GI gastrointestinal, HN head and neck, Gyne Gynecology, SCC squamous cell carcinoma, Adeno adenocarcinoma, Small small cell carcinoma, CC clear cell carcinoma, MRI magnetic resonance imaging, ¹⁸FDG-PET ¹⁸fluorodeoxyglucose-positron emission tomography

ISSN: 1748-717X